Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
VIP-236 by Vincerx Pharma for Endometrial Cancer: Likelihood of Approval
VIP-236 is under clinical development by Vincerx Pharma and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
VIP-236 by Vincerx Pharma for Adenoid Cystic Carcinoma (ACC): Likelihood of Approval
VIP-236 is under clinical development by Vincerx Pharma and currently in Phase I for Adenoid Cystic Carcinoma (ACC). According to...
VIP-236 by Vincerx Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval
VIP-236 is under clinical development by Vincerx Pharma and currently in Phase I for Non-Small Cell Lung Cancer. According to...
VIP-236 by Vincerx Pharma for Solid Tumor: Likelihood of Approval
VIP-236 is under clinical development by Vincerx Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
VIP-236 by Vincerx Pharma for Gastric Cancer: Likelihood of Approval
VIP-236 is under clinical development by Vincerx Pharma and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
VIP-236 by Vincerx Pharma for Colorectal Cancer: Likelihood of Approval
VIP-236 is under clinical development by Vincerx Pharma and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
Enitociclib by Vincerx Pharma for Non-Hodgkin Lymphoma: Likelihood of Approval
Enitociclib is under clinical development by Vincerx Pharma and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...
VIP-943 by Vincerx Pharma for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
VIP-943 is under clinical development by Vincerx Pharma and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...
VIP-943 by Vincerx Pharma for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
VIP-943 is under clinical development by Vincerx Pharma and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
VIP-943 by Vincerx Pharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval
VIP-943 is under clinical development by Vincerx Pharma and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
VIP-943 by Vincerx Pharma for Myelodysplastic Syndrome: Likelihood of Approval
VIP-943 is under clinical development by Vincerx Pharma and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
Enitociclib by Vincerx Pharma for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Enitociclib is under clinical development by Vincerx Pharma and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...